Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

NCT07413952 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
45
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

The First Affiliated Hospital of Guangzhou Medical University